OKYONasdaqBiological Products, (No Diagnostic Substances)
OKYO Pharma Ltd
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 20, 2026
$1.40−0.01 (-0.71%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Who owns OKYO Pharma's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
7 buys · 0 sales
Net bought $136.04K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Point72 Asset Management, L.P. | 4,058,445 | 7.90% | 13G (passive) | Feb 17, 2026 |
| Alex Silverstein | 4,054,054 | 7.70% | 13G (passive) | Mar 31, 2026 |
| Chernett Jorey | 3,802,194 | 9.50% | 13G (passive) amendment | Dec 31, 2025 |
| Woodline Partners LP | 3,652,190 | 7.00% | 13G (passive) | Mar 31, 2026 |
| Laura Natalia Monica Fonda | 1,928,451 | 5.01% | 13G (passive) | Jul 22, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert John Dempsey | CHIEF EXECUTIVE OFFICER, Director | 15,000 | 0.03% | Aug 7, 2026 |
| Gary S. Jacob | CHIEF DEVELOPMENT OFFICER, Director | 112,420 | 0.21% | Aug 7, 2026 |
| Rajkumar V. Patil | Chief Scientific Officer | 20,030 | 0.04% | Aug 7, 2026 |
| Flavio Mantelli | CHIEF MEDICAL OFFICER | 20,000 | 0.04% | Aug 7, 2026 |
| Keeren Rameshchandra Shah | Chief Financial Officer | 16,667 | 0.03% | Jun 10, 2026 |
| Gabriele M. Cerrone | Director, 10% owner | 21,400,332 | 40.78% | Aug 7, 2026 |
| John P. Brancaccio | Director | 35,201 | 0.07% | Aug 7, 2026 |
| Bernard Denoyer | Director | – | – | Jun 10, 2026 |
| Willy Jules Simon | Director | 15,383 | 0.03% | Jun 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rajkumar V. Patil Chief Scientific Officer | Jul 27, 2026 | Buy | +3,363 | $1.49 | $5.01K | 20,030 |
| Rajkumar V. Patil Chief Scientific Officer | Jul 27, 2026 | Award | +3,363 | $1.49 | $5.01K | 20,030 |
| Robert John Dempsey CHIEF EXECUTIVE OFFICER, Director | Jul 22, 2026 | Buy | +15,000 | $1.54 | $23.10K | 15,000 |
| Robert John Dempsey CHIEF EXECUTIVE OFFICER, Director | Jul 22, 2026 | Award | +15,000 | $1.54 | $23.10K | 15,000 |
| Flavio Mantelli CHIEF MEDICAL OFFICER | Jul 21, 2026 | Buy | +20,000 | $1.40 | $28.00K | 20,000 |
| John P. Brancaccio Director | Jul 21, 2026 | Buy | +5,000 | $1.48 | $7.40K | 35,201 |
| Gary S. Jacob CHIEF DEVELOPMENT OFFICER, Director | Jul 21, 2026 | Buy | +3,500 | $1.40 | $4.90K | 112,420 |
| Gabriele M. Cerrone Director, 10% owner | Jul 21, 2026 | Buy | +22,500 | $1.45 | $32.63K | 10,873,916 |
| Gabriele M. Cerrone Director, 10% owner | Jul 21, 2026 | Award | +22,500 | $1.45 | $32.63K | 10,873,916 |
| Gary S. Jacob CHIEF DEVELOPMENT OFFICER, Director | Jul 21, 2026 | Award | +3,500 | $1.40 | $4.90K | 112,420 |
| John P. Brancaccio Director | Jul 21, 2026 | Award | +5,000 | $1.48 | $7.40K | 35,201 |
| Flavio Mantelli CHIEF MEDICAL OFFICER | Jul 21, 2026 | Award | +20,000 | $1.40 | $28.00K | 20,000 |
| Gabriele M. Cerrone Director, 10% owner | Jul 20, 2026 | Buy | +25,000 | $1.40 | $35.00K | 10,851,416 |
| Gabriele M. Cerrone Director, 10% owner | Jul 20, 2026 | Award | +25,000 | $1.40 | $35.00K | 10,851,416 |
| Gabriele M. Cerrone Director, 10% owner | Jun 8, 2026 | Award | +300,000 | $1.72 | $516.00K | 10,826,416 |
| Gabriele M. Cerrone Executive Chairman, Director | Oct 27, 2023 | Other | +70,071 | $1.50 | $105.11K | 9,177,903 |
| Gabriele M. Cerrone Executive Chairman, Director | Oct 23, 2023 | Other | +499,468 | $1.50 | $749.20K | 9,107,832 |
| John P. Brancaccio Director | Sep 15, 2023 | Buy | +16,670 | $1.50 | $25.01K | 16,670 |
| Gabriele M. Cerrone Executive Chairman, Director | May 19, 2022 | Buy | +5,800,000 | $0.08 | $464.00K | 548,981,215 |
| Gabriele M. Cerrone Non-Executive Chairman, Director, 10% owner | May 19, 2022 | Buy | +37,500 | $4.00 | $150.00K | 62,500 |
| Gary S. Jacob Chief Executive Officer, Director | May 19, 2022 | Buy | +12,500 | $4.00 | $50.00K | 12,500 |
| Gabriele M. Cerrone Non-Executive Chairman, Director, 10% owner | May 17, 2022 | Buy | +1,625,000 | $0.06 | $97.50K | 544,806,215 |
| Gabriele M. Cerrone Non-Executive Chairman, Director, 10% owner | May 17, 2022 | Buy | +25,000 | $3.87 | $96.75K | 25,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.